SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Siatis Perry C

(Last) (First) (Middle)
1 N. WAUKEGAN ROAD
AP34

(Street)
NORTH CHICAGO IL 60064

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/17/2022
3. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, GC and Secretary
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $0.01 par value 10,377(1) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (Right to buy)(2) 02/20/2021 02/19/2030 Common Stock 7,364 $93.5 D
Option (Right to buy)(3) 02/18/2022 02/17/2031 Common Stock 7,039 $105.92 D
Option (Right to buy)(4) 02/17/2023 02/16/2032 Common Stock 8,756 $144.54 D
Explanation of Responses:
1. These securities represent restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. They vest in full on February 17, 2025, and include the right to have stock withheld for tax purposes.
2. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,365 shares on 2/20/2021 and as to 7,365 shares on 2/20/2022, and will become exercisable as to 7,364 shares on 2/20/2023.
3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,250 shares on 2/18/2022, and will become exercisable as to 3,250 shares on 2/18/2023 and as to 3,519 shares on 2/18/2024.
4. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 2,919 shares on 2/17/2023, as to 2,919 shares on 2/17/2024 and as to 2,918 shares on 2/17/2025.
Steven L. Scrogham, attorney-in-fact for Perry C. Siatis 10/27/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.